FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2035565581> ?p ?o ?g. }

• W2035565581 endingPage "679" @default.
• W2035565581 startingPage "673" @default.
• W2035565581 abstract "Summary: The effect of the experimental antiepileptic drug zonisamide (l,2-benzisoxazole-3-methanesulfon-amide, ZNS) on the trigeminal complex of cats was compared with the effect of established antiepileptic drugs. Intravenous administration of 10–40 mg/kg ZNS significantly depresses descending excitatory mechanisms, as well as segmental and descending inhibitory mechanisms, but has only a minor effect on segmental excitatory mechanisms. This spectrum of activity is similar to that of valproate, and suggests that ZNS should also be a broad-spectrum antiepileptic drug. In agreement with our experimental observations, it has been found that ZNS is effective against complex partial, generalized tonic clonic, and myoclonic seizures. The antiepileptic profile of ZNS in conventional screening tests resembles that of carbamazepine (CBZ) and phenytoin. However, CBZ exacerbates rather than prevents myoclonic seizures. Our experimental model thus provides a more accurate prediction of ZNS's clinical spectrum of activity. The relationship of these findings to the mechanism of action of antiepileptic drugs is discussed. RÉSUMÉ Nous avons comparé l'effet de la zonisamide (1,2-benzisoxa-zole-3-méthanesulfonamide, ZNS) sur le complexe trigéminé du chat à ceux d'antiépileptiques de référence. L'administration in-traveineuse de 10 à 40 mg/kg de ZNS a significativement dé-primé les mé canismes excitateurs ascendants, ainsi que les mé-canismes inhibiteurs segmentaires et descendants, avec seule-ment un effet mineur sur les mécanismes excitateurs segmentaires. Ce spectre d'activité est similaire à celui du valproate, et suggère que la ZNS devrait être un antiépileptique à large spectre. En accord avec nos constatations expérimentales, il a été constaté que la ZNS est efficace dans les crises partielles complexes, généralisées tonico-cloniques et myocloniques. Le profil anticonvulsivant de la ZNS fourni par les tests convention-nels évoque celui de la carbamazépine (CBZ) et de la phénytoïne. Cependant, la CBZ augmente plus qu'elle ne diminue les phénomènes myocloniques. Notre modèle expérimental a done fourni une prédiction plus juste du spectre d'action clinique de la ZNS. Nous discutons la relation entre ces constatations et le mécanisme d'action des antiépileptiques. RESUMEN Se ha estudiado el efecto antiepiléptico experimental de la zonisamida (l,2-benzisoxazol-3-metanosulfonamida) (ZNS) sobre el complejo trigeminal de los gatos y los resultados se han comparado con el efecto de medicaciones antiepilépticas ya es-tablecidas. La administración intravenosa de 10–40 mg/Kg de ZNS deprimió significativamente los mecanismos excitatorios descendentes así como los mecanismos inhibitorios segmen-tarios y descendentes, mientras que produjo solamente efectos menores sobre los mecanismos excitatorios segmentarios. Este espectro de actividad es semejante a los del valproato y sugiere que la ZNS debería ser también considerada como una droga antiepiléptica de amplio espectro. De acuerdo con nuestras ob-servaciones experimentales se ha encontrado que la ZNS es eficaz contra los ataques parciales complejos, generalizados tónico-clónicos y mioclónicos. El perfil anticonvulsivo de la ZNS, en estudios convencionales, es semejante al de la carba-mazepina (CBZ) y la fenitoina. Sin embargo la CBZ exacerba, mas que previene, los ataques mioclónicos. Este modelo experimental proporciona un previsión más acertada del espectro de actividad qui'mica de la ZNS. Se discute la relación existente entre los mecanismos de estos hallazgos y la accion antiepiléptica de la droga." @default.
• W2035565581 created "2016-06-24" @default.
• W2035565581 creator A5008193735 @default.
• W2035565581 creator A5050943067 @default.
• W2035565581 creator A5067380182 @default.
• W2035565581 date "1987-12-01" @default.
• W2035565581 modified "2023-10-16" @default.
• W2035565581 title "Effect of Zonisamide (CI-912) on a Synaptic System Model" @default.
• W2035565581 cites W1964382934 @default.
• W2035565581 cites W1981916217 @default.
• W2035565581 cites W2017492575 @default.
• W2035565581 cites W2027646648 @default.
• W2035565581 cites W2043102131 @default.
• W2035565581 cites W2051051710 @default.
• W2035565581 cites W2070489331 @default.
• W2035565581 cites W2071712046 @default.
• W2035565581 cites W2077682184 @default.
• W2035565581 cites W2089773466 @default.
• W2035565581 cites W2093695045 @default.
• W2035565581 cites W2096892233 @default.
• W2035565581 cites W2100756613 @default.
• W2035565581 cites W2105647726 @default.
• W2035565581 cites W2164715577 @default.
• W2035565581 cites W2336817565 @default.
• W2035565581 doi "https://doi.org/10.1111/j.1528-1157.1987.tb03699.x" @default.
• W2035565581 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/3691417" @default.
• W2035565581 hasPublicationYear "1987" @default.
• W2035565581 type Work @default.
• W2035565581 sameAs 2035565581 @default.
• W2035565581 citedByCount "12" @default.
• W2035565581 crossrefType "journal-article" @default.
• W2035565581 hasAuthorship W2035565581A5008193735 @default.
• W2035565581 hasAuthorship W2035565581A5050943067 @default.
• W2035565581 hasAuthorship W2035565581A5067380182 @default.
• W2035565581 hasConcept C112592302 @default.
• W2035565581 hasConcept C126322002 @default.
• W2035565581 hasConcept C15744967 @default.
• W2035565581 hasConcept C169760540 @default.
• W2035565581 hasConcept C17077164 @default.
• W2035565581 hasConcept C185592680 @default.
• W2035565581 hasConcept C2775858608 @default.
• W2035565581 hasConcept C2777138316 @default.
• W2035565581 hasConcept C2777683783 @default.
• W2035565581 hasConcept C2778186239 @default.
• W2035565581 hasConcept C2778337148 @default.
• W2035565581 hasConcept C2779253243 @default.
• W2035565581 hasConcept C2994127763 @default.
• W2035565581 hasConcept C71924100 @default.
• W2035565581 hasConcept C98274493 @default.
• W2035565581 hasConceptScore W2035565581C112592302 @default.
• W2035565581 hasConceptScore W2035565581C126322002 @default.
• W2035565581 hasConceptScore W2035565581C15744967 @default.
• W2035565581 hasConceptScore W2035565581C169760540 @default.
• W2035565581 hasConceptScore W2035565581C17077164 @default.
• W2035565581 hasConceptScore W2035565581C185592680 @default.
• W2035565581 hasConceptScore W2035565581C2775858608 @default.
• W2035565581 hasConceptScore W2035565581C2777138316 @default.
• W2035565581 hasConceptScore W2035565581C2777683783 @default.
• W2035565581 hasConceptScore W2035565581C2778186239 @default.
• W2035565581 hasConceptScore W2035565581C2778337148 @default.
• W2035565581 hasConceptScore W2035565581C2779253243 @default.
• W2035565581 hasConceptScore W2035565581C2994127763 @default.
• W2035565581 hasConceptScore W2035565581C71924100 @default.
• W2035565581 hasConceptScore W2035565581C98274493 @default.
• W2035565581 hasIssue "6" @default.
• W2035565581 hasLocation W20355655811 @default.
• W2035565581 hasLocation W20355655812 @default.
• W2035565581 hasOpenAccess W2035565581 @default.
• W2035565581 hasPrimaryLocation W20355655811 @default.
• W2035565581 hasRelatedWork W1969733588 @default.
• W2035565581 hasRelatedWork W1985137475 @default.
• W2035565581 hasRelatedWork W1996109765 @default.
• W2035565581 hasRelatedWork W2038924450 @default.
• W2035565581 hasRelatedWork W2072053288 @default.
• W2035565581 hasRelatedWork W2153335219 @default.
• W2035565581 hasRelatedWork W2312493393 @default.
• W2035565581 hasRelatedWork W2401256813 @default.
• W2035565581 hasRelatedWork W2429723649 @default.
• W2035565581 hasRelatedWork W2906906539 @default.
• W2035565581 hasVolume "28" @default.
• W2035565581 isParatext "false" @default.
• W2035565581 isRetracted "false" @default.
• W2035565581 magId "2035565581" @default.
• W2035565581 workType "article" @default.